{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:55Z","timestamp":1787026555238,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) infection remains a challenge following kidney transplantation (KTx). Currently, CMV-IgG serostatus at transplantation is used to individualize CMV preventive strategies. We assessed the clinical utility of CMV-IGRA for predicting CMV infection following KTx.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a nationwide prospective cohort study from August 2016 until December 2022. Data from all adult KTx recipients in Norway, n=1,546 (R+; n=1,157, D+\/R-; n=260, D-\/R-; 129), were included with a total of 3,556 CMV-IGRA analyses (1,375 at KTx, 1,188 at eight weeks, 993 one-year after KTx) and 35,782 CMV DNAemia analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In R+ recipients CMV-IGRA status, measured at any of the time-points, could not identify any differential risk of later CMV infection. D+\/R- recipients remaining CMV-IGRA negative 1-year after transplantation (regardless of positive CMV DNAemia and\/or CMV IgG status at that time) had increased risk of developing later CMV infection compared to D+\/R- recipients who had become CMV-IGRA positive (14% vs. 2%, p=0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Knowledge of pre-transplant CMV-IGRA status did not provide additional information to CMV-IgG serostatus that could improve current post-transplant CMV treatment algorithms. However, D+\/R- recipients with a persisting negative CMV-IGRA one-year after transplantation remained at increased risk of experiencing later CMV infection. Therefore we advocate post-transplant CMV-IGRA monitoring in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1414830","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:47:16Z","timestamp":1719535636000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Cellular immunity against cytomegalovirus and risk of infection after kidney transplantation"],"prefix":"10.3389","volume":"15","author":[{"given":"Kjersti B.","family":"Blom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grete B.","family":"Kro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Midtvedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond G.","family":"Jenssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Varberg","family":"Reis\u00e6ter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallvor","family":"Rollag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solbj\u00f8rg","family":"Sagedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivar","family":"Sjaastad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth","family":"Tylden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro","family":"Nj\u00f8lstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Nilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon A.","family":"Birkeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00c5sberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1186\/s12889-022-13971-7","article-title":"A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development","volume":"22","author":"Fowler","year":"2022","journal-title":"BMC Public Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1128\/CMR.00034-08","article-title":"Immunobiology of human cytomegalovirus: from bench to bedside","volume":"22","author":"Crough","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12288","article-title":"The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival","volume":"28","author":"Smedbr\u00e5ten","year":"2014","journal-title":"Clin transplantation"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00735.x","article-title":"Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival","volume":"66","author":"Sagedal","year":"2004","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2013.45.3.260","article-title":"Cytomegalovirus infections in solid organ transplantation: a review","volume":"45","author":"Ramanan","year":"2013","journal-title":"Infect Chemother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200531152901","article-title":"Cytomegalovirus in solid organ transplant recipients: clinical updates, challenges and future directions","volume":"26","author":"Razonable","year":"2020","journal-title":"Curr Pharm Des"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200010270-00007","article-title":"A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients","volume":"70","author":"Sagedal","year":"2000","journal-title":"Transplantation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12879-018-3075-z","article-title":"Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients","volume":"18","author":"Deborska-Materkowska","year":"2018","journal-title":"BMC Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000438025.96334.eb","article-title":"Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant","volume":"97","author":"L\u00f3pez-Oliva","year":"2014","journal-title":"Transplantation"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001825","article-title":"CMV-specific T cell monitoring offers superior risk stratification of CMV-seronegative kidney transplant recipients of a CMV-seropositive donor","volume":"101","author":"Schachtner","year":"2017","journal-title":"Transplantation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1097\/TP.0000000000004870","article-title":"QuantiFERON-CMV as a predictor of CMV events during preemptive therapy in CMV-seropositive kidney transplant recipients","volume":"108","author":"Reusing","year":"2023","journal-title":"Transplantation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/cid\/ciad575","article-title":"Immune monitoring-guided vs fixed duration of antiviral prophylaxis against cytomegalovirus in solid-organ transplant recipients. A Multicenter, Randomized Clinical Trial","volume":"78","author":"Manuel","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11527","DOI":"10.3389\/ti.2023.11527","article-title":"Utility of the interferon-gamma enzyme-linked immunosorbent spot assay to predict risk of cytomegalovirus infection in kidney transplant recipients","volume":"36","author":"Namsiripongpun","year":"2023","journal-title":"Transpl Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14347","article-title":"An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation","volume":"17","author":"Kumar","year":"2017","journal-title":"Am J Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2006.00199.x","article-title":"Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV","volume":"9","author":"Walker","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00563-13","article-title":"Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients","volume":"51","author":"Abate","year":"2013","journal-title":"J Clin Microbiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1097\/TP.0000000000004615","article-title":"Cytomegalovirus high-risk kidney transplant recipients show no difference in long-term outcomes following preemptive versus prophylactic management","volume":"107","author":"Blom","year":"2023","journal-title":"Transplantation"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit096","article-title":"Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients","volume":"56","author":"Razonable","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12738","article-title":"Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience","volume":"21","author":"St\u00f8rset","year":"2016","journal-title":"Nephrol (Carlton)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13012","article-title":"Factors related to the development of CMV-specific CD8+ T cell response in CMV-seropositive solid organ transplant candidates","volume":"15","author":"Cantis\u00e1n","year":"2015","journal-title":"Am J Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12049","article-title":"Pretransplant interferon-\u03b3 secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation","volume":"13","author":"Cantis\u00e1n","year":"2013","journal-title":"Am J Transplant"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02618.x","article-title":"Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients","volume":"9","author":"Kumar","year":"2009","journal-title":"Am J Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2019.11.002","article-title":"Monitoring of CMV-specific cell-mediated immunity in kidney transplant recipients with a high risk of CMV disease (D+\/R-): A case series","volume":"52","author":"Andreani","year":"2020","journal-title":"Transplant Proc"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02294.x","article-title":"Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity","volume":"8","author":"Westall","year":"2008","journal-title":"Am J Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"7194","DOI":"10.1038\/s41598-020-64133-x","article-title":"Lack of cytomegalovirus (CMV)-specific cell-mediated immune response using QuantiFERON-CMV assay in CMV-seropositive healthy volunteers: fact not artifact","volume":"10","author":"Valle-Arroyo","year":"2020","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.893232","article-title":"QuantiFERON-cytomegalovirus assay for prediction of cytomegalovirus viremia in kidney transplant recipients: study from high cytomegalovirus seroprevalence country","volume":"12","author":"Pongsakornkullachart","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1209","article-title":"Cellular immunity to predict the risk of cytomegalovirus infection in kidney transplantation: A prospective, interventional, multicenter clinical trial","volume":"71","author":"Jarque","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12256","article-title":"Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation","volume":"13","author":"Bestard","year":"2013","journal-title":"Am J Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis818","article-title":"State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician","volume":"55","author":"Egli","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01716-21","article-title":"Utility of cytomegalovirus cell-mediated immunity assays in solid organ transplantation","volume":"60","author":"Hall","year":"2022","journal-title":"J Clin Microbiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1414830\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:47:19Z","timestamp":1719535639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1414830\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2024.1414830"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1414830","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]},"article-number":"1414830"}}